The two-year diabetes analysis compared the clinical outcomes associated with the Resolute DES in 878 standard risk diabetes patients, to 1,903 patients without diabetes enrolled in the Resolute clinical programme.
The Food and Drug Administration (FDA)-approved Resolute DES analysis showed consistently low event rates for both groups, despite the higher-risk nature of the diabetes patient population.
At two years of follow-up, rates of target lesion failure (TLF), defined as cardiac death, target vessel myocardial infarction and target lesion revascularisation (a repeat procedure to treat the same arterial segment), were 7.1% for patients without diabetes and 9.6% for patients with diabetes.
Scott Lee, clinical professor of medicine at Loma Linda University Medical Center , US, and medical director of global clinical research for Medtronic Diabetes in Northridge, said that clinically validated and minimally invasive treatment options for patients with both coronary artery disease and diabetes represented an unmet clinical need for the diabetes community.
"Considering the challenges that are presented when treating diabetes patients with CAD, physicians can have confidence in the consistently low event rates in both patients with and without diabetes, when using this device," Lee added.
The two-year analysis also evaluated safety measures, comparing insulin-dependent and non-insulin-dependent diabetes patients to patients without diabetes.
In collaboration with clinicians, researchers and scientists worldwide, Medtronic offers a range of medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias.